Petter Bjornstad

Mar 1, 2023 | jci.org | Katherine R. Tuttle |Jennifer Schaub |Matthias Kretzler |Petter Bjornstad

AbstractThe sodium-glucose cotransporter-2 (SGLT2) is expressed on the luminal side of proximal tubule epithelial cells in the kidney. While pharmacological inhibition of SGLT2 provides kidney protection in diabetic kidney disease (DKD), the molecular mechanisms remain unclear. In this issue of the JCI, Schaub et al. report on the changes in single-cell transcriptional profiles of young participants with type 2 diabetes who received SGLT2 inhibitors.